Cell-based bioassays often pose a hurdle during a rapidly moving biologics development program. High standards for assay accuracy, precision, reproducibility…
Read MoreSearch results: “Abl”
Showing 49–60 of 95 results
Class I therapeutic antibodies achieve their clinical efficacy not only by binding to their target antigen, but also through Fc…
Read MoreFollowing the recent regulatory approvals of a number of checkpoint inhibitor therapeutics, development of a wide array of immunomodulatory therapeutic…
Read MoreDiscoveRx has pioneered a novel enzyme complementation system to monitor cellular events such as protein translocation, protein interactions, and degradation…
Read MoreKinase targets have been extensively studied in biochemical assays using purified protein fragments for the kinase and the substrate. However,…
Read MoreDiscoveRx® has pioneered a novel enzyme complementation system to monitor cellular events such as protein translocation, protein interactions, and degradation…
Read MoreDiscoveRx® has pioneered a novel enzyme complementation system to monitor cellular events such as protein translocation, protein interactions, and degradation…
Read MoreReporter genes are a well-established method used to develop cell-based assays for testing drugs that inhibit targets involved in specific…
Read MoreThe PathHunter™ technology from DiscoveRx is an adaptation of Enzyme Fragment Complementation (EFC) that provides a novel, generic cell-based assay…
Read MoreUbiquitin-mediated degradation of signaling proteins is a primary means of signal regulation in a wide variety of cellular processes including…
Read MoreThe recent appreciation of functional selectivity/ligand bias in GPCR signaling has uncovered new opportunities for therapeutic discovery and continues to…
Read MoreKinase targets have been extensively studied in biochemical assays using purified protein fragments for the kinase and the substrate. However,…
Read More